Aqueous proteins help predict the response of patients with neovascular age-related macular degeneration to anti-VEGF therapy.

ABSTRACT: BackgroundTo reduce the treatment burden for patients with neovascular age-related macular degeneration (nvAMD), emerging therapies targeting vascular endothelial growth factor (VEGF) are being designed to extend the interval between treatments, thereby minimizing the number of intraocular injections. However, which patients will benefit from longer-acting agents is not clear.MethodsEyes with nvAMD (n = 122) underwent 3 consecutive monthly injections with currently available anti-VEGF therapies, followed by a treat-and-extend protocol. Patients who remained quiescent 12 weeks from their prior treatment entered a treatment pause and were switched to pro re nata (PRN) treatment (based on vision, clinical exam, and/or imaging studies). Proteomic analysis was performed on aqueous fluid to iden

SUBMITTER: Cao X 

PROVIDER: S-EPMC8759792 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature